Inicio de la web del Complejo Hospitalario Universitario de Albacete

Saltar a contenidos
Decoracion. Fotomontaje de dos medicos observando una radiografia junto con el logotipo del Hospital.

Opciones Generales

Barra de navegación

Esta usted en:
Compartir en FacebookCompartir en Twitter
Aumentar tamao del texto..
Tamao normal del texto..
Disminuir tamao del texto..
Escuche el contenido de esta pgina. Se abrir una nueva ventana..

Menú lateral de opcciones


Publicaciones

Contenido

  1. Tibau A, Bedard PL, Srikanthan A, Ethier JL, Vera-Badillo FE, Templeton AJ, Ocaña A, Seruga B, Barnadas A, Amir E. Author financial conflicts of interest, industry funding, and clinical practice guidelines for anticancer drugs. J Clin Oncol. 2015 Jan 1;33(1):100-6 (Factor de impacto 18,44 ) Cuartil 1.

  2. Montero JC, Esparís-Ogando A, Re-Louhau MF, Seoane S, Abad M, Calero R, Ocaña A, Pandiella A. Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer. Oncogene. 2014 Jan 9;33(2):148-56 (Factor de impacto 8,459 ) Cuartil 1

  3. Vera-Badillo FE, Templeton AJ, de Gouveia P, Diaz-Padilla I, Bedard PL, Al-Mubarak M, Seruga B, Tannock IF, Ocana A, Amir E. Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 2014 Jan;106(1):djt319 (Factor de impacto 12,583 ) Cuartil 1

  4. Al-Mubarak M, Tibau A, Templeton AJ, Cescon DW, Ocana A, Seruga B, Amir E. Extended adjuvant tamoxifen for early breast cancer: a meta-analysis. PLoS One. 2014 Feb 20;9(2):e88238. (Factor de impacto 3,53 ) Cuartil 1

  5. Ocaña A, Freedman O, Amir E, Seruga B, Pandiella A. Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors. Cancer Metastasis Rev. 2014 Mar;33(1):295-307 (Factor de impacto 7,23 ) Cuartil 1

  6. Ocana A, Vera-Badillo F, Al-Mubarak M, Templeton AJ, Corrales-Sanchez V, Diez-Gonzalez L, Cuenca-Lopez MD, Seruga B, Pandiella A, Amir E. Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis. PLoS One. 2014 Apr 28;9(4):e95219. (Factor de impacto 3,53 ) Cuartil 1

  7. Cuenca-López MD, Montero JC, Morales JC, Prat A, Pandiella A, Ocana A. Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling. BMC Cancer. 2014 Apr 30;14:302. (Factor de impacto 3,36 ) Cuartil 2

  8. Seruga B, Zadnik V, Kuhar CG, Marinko T, Cufer T, Zakotnik B, Zorman D, Ocana A, Amir E. Association of aromatase inhibitors with coronary heart disease in women with early breast cancer. Cancer Invest. 2014 May;32(4):99-104. (Factor de impacto 2,21 ) Cuartil 3

  9. Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014 May 29;106(6):dju124. (Factor de impacto 13,58 ) Cuartil 1

  10. Vera-Badillo FE, Napoleone M, Ocana A, Templeton AJ, Seruga B, Al-Mubarak M, AlHashem H, Tannock IF, Amir E. Effect of multifocality and multicentricity on outcome in early stage breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2014 Jul;146(2):235-44 (Factor de impacto 3,94 ) Cuartil 1

  11. Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Hermanns T, Seruga B, Ocaña A, Tannock IF, Amir E. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1204-12. (Factor de impacto 4,125 ) Cuartil 1

  12. Vera-Badillo FE, Ocana A, Templeton AJ, Tibau A, Amir E, Tannock IF. Raising concern about the American Society of Clinical Oncology conflict of interest policy amendment. J Clin Oncol. 2014 Oct 1;32(28):3197. (Factor de impacto 18,44 ) Cuartil 1

  13. Templeton AJ, Diez-Gonzalez L, Ace O, Vera-Badillo F, Seruga B, Jordán J, Amir E, Pandiella A, Ocaña A. Prognostic relevance of receptor tyrosine kinase expression in breast cancer: a meta-analysis. Cancer Treat Rev. 2014 Oct;40(9):1048-55 (Factor de impacto 7,58 ) Cuartil 1

  14. Niraula S, Amir E, Vera-Badillo F, Seruga B, Ocana A, Tannock IF. Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysis. J Clin Oncol. 2014 Nov 10;32(32):3634-42. (Factor de impacto 18,44 ) Cuartil 1

  15. Ortiz-Ruiz MJ, Álvarez-Fernández S, Parrott T, Zaknoen S, Burrows FJ, Ocaña A, Pandiella A, Esparís-Ogando A. Therapeutic potential of ERK5 targeting in triple negative breast cancer. Oncotarget. 2014 Nov 30;5(22):11308-18. (Factor de impacto 6,36 ) Cuartil 1

  16. Ocaña A, Montero JC, Pandiella A. Achilles' heel of triple negative cancer. Oncoscience. 2014 Dec 13;1(12):763-4 (Factor de impacto 6,36 ) 

  17. Brana I, Ocana A, Chen EX, Razak AR, Haines C, Lee C, Douglas S, Wang L, Siu LL, Tannock IF, Bedard PL. A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin. Invest New Drugs. 2014 Dec;32(6):1269-77 (Factor de impacto 2,92 ) Cuartil 2

  18. Tibau A, Bedard PL, Srikanthan A, Ethier JL, Vera-Badillo FE, Templeton AJ, Ocaña A, Seruga B, Barnadas A, Amir E. Author financial conflicts of interest, industry funding, and clinical practice guidelines for anticancer drugs. J Clin Oncol. 2015 Jan 1;33(1):100-6 (Factor de impacto 18,44 ) Cuartil 1

  19. Ocana A, Seruga B, Amir E. Pathological complete response in breast cancer. Lancet. 2015 Jan 10;385(9963):113. (Factor de impacto 45,21 ) Cuartil 1

  20. Vera-Badillo FE, Templeton AJ, Duran I, Ocana A, de Gouveia P, Aneja P, Knox JJ, Tannock IF, Escudier B, Amir E. Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis. Eur Urol. 2015 Apr;67(4):740-9 (Factor de impacto 13,93 ) Cuartil 1

  21. Ocana A, Díez-González L, Garcia-Olmo DC, Templeton AJ, Vera-Badillo F, Gascon-Escribano MJ, Serrano-Heras G, Corrales-Sanchez V, Seruga B, Andrés-Pretel F, Pandiella A, Amir E. Circulating DNA and survival in solid tumors. Cancer Epidemiol Biomarkers Prev. 2015 Nov 24 (Factor de impacto 4,125 ) Cuartil 1

  22. AlHashem HY, Al-Mubarak M, Vera-Badillo FE, Templeton AJ, Ocana A, Seruga B, Amir E. Impact of Geographic Region on Benefit of Approved Anticancer Drugs Evaluated in International Phase III Clinical Trials. Clin Oncol (R Coll Radiol). 2015 Nov 2 (Factor de impacto 18,44 ) Cuartil 1

  23. Seruga B, Ocana A, Amir E, Tannock IF. Failures in Phase III: Causes and Consequences. Clin Cancer Res. 2015 Oct 15;21(20):4552-60 (Factor de impacto 8,7 ) Cuartil 1

  24. Ocana A, Ethier JL, Díez-González L, Corrales-Sánchez V, Srikanthan A, Gascón-Escribano MJ, Templeton AJ, Vera-Badillo F, Seruga B, Niraula S, Pandiella A, Amir E. Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. Oncotarget. 2015 Nov 24;6(37):39538-49 (Factor de impacto 6,36 ) Cuartil 1

  25. Pandiella A, Morís F, Ocaña A, Núñez LE, Montero JC. Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2. Oncotarget. 2015 Oct 20;6(32):32856-67 (Factor de impacto 6,36 ) Cuartil 1

  26. Serrano-Heras G, Cuenca-López MD, Montero JC, Corrales-Sanchez V, Morales JC, Núñez LE, Morís F, Pandiella A, Ocaña A. Phospho-kinase profile of colorectal tumors guides in the selection of multi-kinase inhibitors. Oncotarget. 2015 Oct 13;6(31):31272-83. (Factor de impacto 6,36 ) Cuartil 1

  27. Seoane S, Montero JC, Ocaña A, Pandiella A. Breast cancer dissemination promoted by a neuregulin-collagenase 3 signalling node. Oncogene. 2015 Sep 14. doi: 10.1038/onc.2015.337. [Epub ahead of print] (Factor de impacto 8,459 ) Cuartil 1

  28. Montero JC, García-Alonso S, Ocaña A, Pandiella A. Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling. Oncotarget. 2015 Oct 6;6(30):30057-71 (Factor de impacto 6,36 ) Cuartil 1

  29. Cuenca-López MD, Serrano-Heras G, Montero JC, Corrales-Sánchez V, Gomez-Juarez M, Gascón-Escribano MJ, Morales JC, Voisin V, Núñez LE, Morís F, Bader GD, Pandiella A, Ocaña A. Antitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancer. Oncotarget. 2015 Sep 29;6(29):27923-37. (Factor de impacto 6,36 ) Cuartil 1

  30. Ocana A, Vera-Badillo F, Templeton A, Tannock I, Amir E. Response. J Natl Cancer Inst. 2015 Aug 17;107(10). (Factor de impacto 13,58 ) Cuartil 1

  31. Chan M, Chang MC, González R, Lategan B, del Barco E, Vera-Badillo F, Quesada P, Goldstein R, Cruz I, Ocana A, Cruz JJ, Amir E. Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer. PLoS One. 2015 Jul 10;10(7):e0132449. (Factor de impacto 3,53 ) Cuartil 1

  32. Niraula S, Ocana A, Amir E. One step forward, two steps back: The story of everolimus in advanced breast cancer. Breast. 2015 Oct;24(5):529-31 (Factor de impacto 2,58 ) Cuartil 3

  33. Vera-Badillo FE, Chang MC, Kuruzar G, Ocana A, Templeton AJ, Seruga B, Goldstein R, Bedard PL, Tannock IF, Amir E. Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer. J Clin Pathol. 2015 Oct;68(10):839-43. (Factor de impacto 7,42 ) Cuartil 2

  34. Srikanthan A, Ethier JL, Ocana A, Seruga B, Krzyzanowska MK, Amir E. Cardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational study. PLoS One. 2015 Mar 27;10(3):e0122735 (Factor de impacto 3,53 ) Cuartil 1

  35. Ocaña A, Diez-Gónzález L, Adrover E, Fernández-Aramburo A, Pandiella A, Amir E. Tumor-infiltrating lymphocytes in breast cancer: ready for prime time? J Clin Oncol. 2015 Apr 10;33(11):1298-9. (Factor de impacto 18,44 ) Cuartil 1

  36. Templeton AJ, Ace O, Amir E, Vera-Badillo F, Ocana A, Pond GR, Tannock IF. Influence of censoring on conclusions of trials for women with metastatic breast cancer. Eur J Cancer. 2015 Apr;51(6):721-4.  (Factor de impacto 4,82 ) Cuartil 2

  37. Hernández A, Garcia-Delgado P, Garcia-Cardenas V, Ocaña A, Labrador E, Orera ML, Martinez-Martinez F. Characterization of patients' requests and pharmacists' professional practice in oropharyngeal condition in Spain. Int J Clin Pharm. 2015 Apr;37(2):300-9. doi (Factor de impacto 1,35 ) Cuartil 3

  38. Vera-Badillo FE, Templeton AJ, Duran I, Ocana A, de Gouveia P, Aneja P, Knox JJ, Tannock IF, Escudier B, Amir E. Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis. Eur Urol. 2015 Apr;67(4):740-9.  (Factor de impacto 19,93 ) Cuartil 1

  39. Ocana A, Pandiella A. Novel Synthetic Lethality Approaches for Drug Combinations and Early Drug Development. Curr Cancer Drug Targets. 2015 Dec 3. [Epub ahead of print] (Factor de impacto 3,52 ) Cuartil 2

 

 

Volver

Pie de página

Complejo Hospitalario Universitario de Albacete. Webmaster. Todos los derechos reservados. Nota Legal.


HTML 4.01 Transitional válido - CSS Válido - Icono de conformidad con el Nivel Triple-A, de las Directrices de Accesibilidad para el Contenido Web 1.0 del W3C-WAI - Validado por TAW